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Abstract: ‘Foamy’ alveolar macrophages (FAM) observed in nonclinical toxicology studies during
inhaled drug development may indicate drug-induced phospholipidosis, but can also derive from
adaptive non-adverse mechanisms. Orally administered amiodarone is currently used as a model of
pulmonary phospholipidosis and it was hypothesized that aerosol administration would produce
phospholipidosis-induced FAM that could be characterized and used in comparative inhalation
toxicology. Han-Wistar rats were given amiodarone via (1) intranasal administration (6.25 mg/kg) on
two days, (2) aerosol administration (3 mg/kg) on two days, (3) aerosol administration (10 mg/kg)
followed by three days of 30 mg/kg or (4) oral administration (100 mg/kg) for 7 days. Alveolar
macrophages in bronchoalveolar lavage were evaluated by differential cell counting and high content
fluorescence imaging. Histopathology and mass-spectrometry imaging (MSI) were performed on
lung slices. The higher dose aerosolised amiodarone caused transient pulmonary inflammation
(p < 0.05), but only oral amiodarone resulted in FAM (p < 0.001). MSI of the lungs of orally
treated rats revealed a homogenous distribution of amiodarone and a putative phospholipidosis
marker, di-22:6 bis-monoacylglycerol, throughout lung tissue whereas aerosol administration resulted
in localization of both compounds around the airway lumen. Thus, unlike oral administration,
aerosolised amiodarone failed to produce the expected FAM responses.
Keywords: phospholipidosis; amiodarone; foamy alveolar macrophages; di-22:6
bis-monoacylglycerol; mass spectrometry imaging; high content analysis
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1. Introduction
Inhaled therapies for asthma were first developed in the 1950s and remain the preferred route
of administration for treating the disease [1]. However, there have been few new classes of drugs
licensed during the past 50 years, with many that perform well in pre-clinical animal studies failing in
pre-clinical development owing to a lack of safety and/or efficacy in humans [2]. Failure to translate
promising drug effects from pre-clinical assays and animal studies to humans has led to questions
regarding the relevance of current pre-clinical models, and a demand for more predictive in vivo and
in vitro tools.
One of the difficulties in non-clinical assessment of inhaled drug safety is uncertainties around the
alveolar macrophage (AM) response in animals and its relevance to safety in the clinic [2]. A typical
finding in toxicity studies with inhaled formulations of new drugs is the induction of foamy alveolar
macrophages (FAM) which may or may not be indicative of subsequent adverse events. Despite not
knowing the longer term effects of inducing FAM, the presence of such cells in the lung in toxicology
experiments can stop the further development of inhaled drug candidates. “Foamy macrophage”
is a term used to describe the vacuolated, enlarged appearance of an AM, observable by light
microscopy, due to the presence of lamellar bodies, or an accumulation of lipids or drug particles in
the cytoplasm [2,3]. It is often unclear whether macrophage responses are due to general particulate
overload [4] or pharmacologically-driven [2,5] and it is thought that different pathways underpin
different mechanisms. The foamy appearance may also be accompanied by increase in macrophage
numbers and activation. Any of these effects may represent an adaptive response to the administered
material or the initial stages of an adverse effect.
The inability to discriminate between adaptive and adverse responses triggers additional in vivo
assessments to determine whether there are secondary consequences of FAM appearance, such as
inflammation, and to make go/no-go decisions on candidate drugs progressing to clinic phases of
development which can lead to drugs exhibiting this effect being discontinued, perhaps prematurely,
from further development. To improve inhaled drug development, a better understanding is required
of FAM biology and the significance of this finding when observed in species routinely used to predict
safety of inhaled medicines to be used in humans. This knowledge would hopefully lead to better
lead compound selection and a reduction in the costly and repetitive toxicological studies in animals
required to optimise safe doses of inhaled medicines.
Previous work in our laboratory has focused on the design of an in vitro high content “foamy
macrophage” assay platform [4] that may be used in the early development stages to screen for
problematic compounds or formulations with the aim of excluding them from the development
pathway prior to animal studies. Based on automated fluorescence imaging, the high content analysis
(HCA) assay provides quantitative data on morphometric parameters and vacuolation patterns, and can
be combined with a variety of markers for phenotypic and functional characterisation of macrophages.
Amiodarone has been used as a positive control to induce a FAM appearance in the development of
the in vitro screening platform and was therefore selected as a model compound to investigate how
well the in vitro assay outputs correlate with macrophages lavaged from an in vivo model following
treatment with this drug when administered by inhalation.
Amiodarone is a prototypic cationic amphiphilic drug (CAD), well-known for its pulmonary
toxicity profile and ability to induce phospholipidosis in the AM population [6–8]. Oral administration of
amiodarone is associated with serious pulmonary toxicity, including acute or subacute pneumonitis [8,9],
alveolitis [10], pulmonary infiltrates, pleural disease, and the abnormal accumulation of phospholipids
in cells and tissues [6,8,10–12], without resulting in fibrosis [12,13]. As well as the inflammatory
effects, there is significant evidence of macrophages developing a foamy phenotype [7,14–17]. When
administered intratracheally (i.t.) amiodarone causes pulmonary fibrosis [18–20] as well as an increase
in the number of inflammatory cells (macrophages, neutrophils and eosinophils) recovered from
bronchoalveolar lavage (BAL) [12,18,19,21].
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In this study, it was hypothesised that administration of amiodarone as an inhaled dry powder
would provide a more evenly distributed, physically and quantitatively relevant exposure scenario
compared to intranasal (i.n.), i.t. instillation or oral administration, and therefore provide an appropriate
model and positive control for studying the FAM response to inhaled medicines. The effects of inhaled
amiodarone powder aerosols have not been reported previously. Therefore, the aim of this study
was to characterise the effects of an inhaled powder formulation of amiodarone in the rat, a species
commonly used in regulatory toxicology experiments. Prior to the main aerosol study, a small number
of animals were dosed intranasally with 6.25 mg/kg amiodarone (on two alternate days) to evaluate
dose tolerability in Wistar Han rats, since previous reports in the literature on i.t. instillation of
amiodarone (also 6.25 mg/kg) to F344 rats described rather severe toxicological effects ranging from
inflammation to pulmonary fibrosis [18,19]. As a further comparison, an oral dosing study (100 mg/kg
over seven consecutive days) was performed, such that the results from all administration routes could
be compared within the same study. We evaluated BAL fluid inflammatory markers and used the HCA
assay platform to characterise the BAL macrophage population, as well as conventional histopathology
and mass-spectrometry imaging (MSI) of lung tissue slices. Results of the HCA analysis were compared
with data from a previous in vitro investigation of amiodarone exposure to a rat macrophage cell line
and primary rat cells from naïve rat lungs in order to determine whether in vitro HCA results reflect
the in vivo response.
2. Materials and Methods
2.1. Materials
Methanol (LC-MS grade) was purchased from Fisher Scientific (Leicestershire, UK); purified
water, ELGA Purelab Option (Marlow, UK); MALDI matrices and analytes, 2,5-dihydroxybenzoic acid
(2,5-DHB, >99%), 9-aminoacrinid (9AA, ≥99.5%), d-(+)-raffinose pentahydrate (≥98%) were purchased
from Sigma-Aldrich (Dorset, UK) and used as supplied. Amiodarone hydrochloride (≥98%) was
purchased from Sigma-Aldrich (Dorset, UK) and used as supplied or blended with lactose monohydrate,
Lactohale (GMS 15284, Grade 4), EP and USP and JP, bovine (DFE Pharma, Goch, Germany) for use by
inhalation. All other materials were of analytical grade.
2.2. Amiodarone Characterisation
2.2.1. Aerodynamic Particle Sizer
Aerosols were monitored using a TSI aerodynamic particle sizer (APS) during pre-study aerosol
generation trials and during inhalation exposure of animals; data from the APS was used to further
validate this system, but was not used to report the achieved dose or particle size. The APS was
sampled at a calibrated flow rate of 0.2 L/min for a period of 30 s every minute. The APS data was
used to confirm that particle number and size were consistent with expected values determined from
pre-study aerosol generation trials.
2.2.2. Chemical Analysis of Amiodarone and Target Dose
Amiodarone was micronised to give a mass median aerodynamic diameter of 2.1 µm with a
geometric standard deviation of 2.1, indicating that the particle size was consistent and within the
respirable range of 1–3 µm for rats. The amiodarone concentration in each exposure chamber was
determined in duplicate during inhalation exposure of animals. Samples were taken from a sampling
port by drawing a measured volume of air through a 37 mm GF-A glass fibre filter at a rate of 2.0 L/min
for 1 min fitted to an open face sampler attached to the chamber sampling port. The filters were
weighed before and after sampling for gravimetric analysis of total particulate concentration. For
particle size measurements a measured volume of air was drawn through a Marple personal cascade
impactor (model 296) attached to a sampling pump from the exposure chamber at a rate of 2.0 L/min
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for 1 min. All concentrations and particle size samples were analysed within the Safety Assessment
Dispensary Group at GlaxoSmithKline, Ware, UK. The target dose for protocol one and protocol two
was calculated using the Alexander equation [22]:
DD =
(CC×RMV× T)
BW
. (1)
The RMV for rats was calculated according to the formula:
RMV (L/min) = 0.608× BW (kg)0.852, (2)
where: DD (mg/kg) = Delivered Dose (whole body dose); CC (mg/L) = Cloud Concentration = amount
on filter (0.575 mg)/filter sample volume (4 L) (filter sample volume = filter sample rate (2 L/min) ×
filter sample time (2 min)); RMV (L/min) = Respiratory Minute Volume (0.25 L/min); T (min) = Time of
Exposure; BW (kg) = Body Weight (average weight of rats during a dose run).
2.3. Animals
All experiments were approved by the Home Office and conducted in accordance with the
Animals (Scientific Procedures) Act 1986. Protocols were approved by the local ethics committee of
King’s College London and by the GSK animal welfare and ethical review committee (AWERB), 18
February 2016, project identification code: N37752-1/SP1600088. In vivo experiments were performed
with male Wistar Han rats supplied by Charles River, 7–9 weeks of age (approximately 250–300 g).
2.4. Dosing of Amiodarone
2.4.1. Intranasal Administration of Amiodarone
Amiodarone hydrochloride (6.25 mg/mL stock solution) [18] was dissolved in saline at 60–65 ◦C [20,21]
and allowed to cool to room temperature. On days −2 and 0 rats were anaesthetised with isoflurane 3–5%
v/v in O2 at a flow rate of 1.0 L/min before i.n. administration of amiodarone (6.25 mg/kg) or vehicle, 0.9%
physiological saline, to the lungs [18,19]. Rats were observed until consciousness was regained, then
returned to their home cages and holding room (unless euthanised).
2.4.2. Aerosol Administration of Amiodarone (Dosing Protocol One)
All rats were placed in restraint cones and attached randomly to one of the 24 ports on the
aerosolised dust generation (ADG) tower. On days −2 and 0, control rats were exposed to air for 30
min using the capsule-based aerosol generator (CBAG) mechanism under the same conditions for dry
powder inhalation. On days −2 and 0, another cohort of rats were exposed for 30 min to a dry powder
aerosol of 100% micronised amiodarone, target dose 3 mg/kg using the CBAG mechanism with a baﬄe
in the nozzle section. A total of 204 capsules, each filled with 1 mg of micronised amiodarone, were
used for the inhalation dosing session.
2.4.3. Aerosol Administration of Amiodarone (Dosing Protocol Two)
All rats were placed in restraint cones and attached randomly to one of the 24 ports on the ADG
tower. Animals were dosed with either air or 15% micronised amiodarone in 85% inhalation grade
lactose for 30 min with increasing daily doses of 10 mg/kg (day −3) and 30 mg/kg (days −2, 1 and 0)
using a Wright’s dust feeder (WDF).
2.4.4. Oral Administration of Amiodarone
Male Wistar Han rats (Charles River), of slightly larger body weight (300–395 g) were dosed orally
by gavage using nelaton catheters (size 8) with amiodarone (hydrochloride salt) 100 mg/kg, suspended
in 1% w/v methylcellulose for seven consecutive days.
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2.5. Differential Cell Counts of BAL Cellular Fraction
Rats were sacrificed humanely with an overdose of sodium pentobarbitone (400 mg/rat)
administered intra-peritoneally on days 1, 7 or 28 post-dosing. Death was confirmed by exsanguination.
The lungs were instilled with 3 × 5 mL BAL rinse fluid (3.72 g ethylenediaminetetraacetic acid/1 g
bovine serum albumin/L in phosphate buffered saline (PBS)). The total number of cells were counted
using an Improved Neubauer haemocytometer. Cytospin preparations were stained with Diff-Quick
(Thermo Fisher Scientific, Waltham, MA, USA) for differential cell count quantification. A total of
200 cells were evaluated to determine the proportion of neutrophils, eosinophils and macrophages
using standard morphological criteria. The AM population was further assessed by evaluating 100
macrophages to subcategorise their morphology as normal, foamy or coarsely vacuolated.
2.6. High Content Analysis of BAL Macrophages
Rat AM recovered from the cellular fraction of the BAL were centrifuged at 250 G for 5 min at
4 ◦C. Cell pellets were re-suspended in 1 mL of complete culture medium comprising of phenol red
free RPMI-1640 medium (Sigma-Aldrich, Dorset, UK) supplemented with 10% v/v heat inactivated
fetal bovine serum (Sigma-Aldrich, Dorset, UK), 2 mM l-glutamine (Sigma-Aldrich, Dorset, UK) and
100 IU/mL penicillin/100 µg/mL streptomycin (Gibco, Life Technologies, Paisley, UK). For experiments,
cells were seeded onto bottom clear black 96-well plates (Greiner Bio-One, Gloucester, UK) at a density
of 1.5 × 104 cells/well in 100 µL of complete cell culture medium. The plate was centrifuged at 380 g for
5 min at 20 ◦C and the cells were then incubated for 2 h in a humidified atmosphere at 37 ◦C with 5%
v/v CO2 for macrophage attachment [23] before undergoing the fluorescence staining procedure.
Once the cells had attached to the 96-well plate after 2 h isolation, non-adherent cells were
aspirated and 200 µL of fresh phenol red free media was added to all wells containing cells. Cell health
and morphology assessment was completed according to an established protocol [24]. In brief, cells
were incubated for 30 min with a florescent staining cocktail containing: Hoechst 33342 (10 µg/mL),
MitoTracker Red (300 nM) and Image-It Dead Green (25 nM) (Invitrogen, Renfrewshire, UK), followed
by washing with 100 µL PBS, and fixed with 4% w/v paraformaldehyde for 15 min. The cell cytoplasm
was with Cell Mask Deep Red (Invitrogen, Renfrewshire, UK) diluted 1:1000 (according to the
manufacturer’s protocol) for 100 min in the dark at 25 ◦C. Cells were then washed once with PBS as
described above before imaging.
To quantify lipid content, cells were seeded onto 96-well plates at the density of 1.5 × 104 cells/well,
in complete cell culture media containing HCS LipidTox Phospholipid Red (Invitrogen, Renfrewshire,
UK) diluted 1:1000 (according to the manufacturer’s protocol). The cells were incubated for 2 h in a
humidified atmosphere at 37 ◦C with 5% v/v CO2. Following incubation cells were washed once with
100 µL PBS and fixed for 20 min with 4% w/v paraformaldehyde containing Hoechst 33342 (10 µg/mL).
Cells were washed once with 100 µL PBS before incubation with HCS LipidTox Green (diluted 1:1000)
for 30 min for detection of neutral lipids.
Cells from both assays were imaged using the In Cell Analyser 6000 (GE Healthcare, Little
Chalfont, Bucks, UK). Images in standard 2D mode were captured with a 40× objective. Internal
controls of untreated cells contained 200 µM carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone
as a mitochondrial activity control and 0.5% v/v Triton X-100 as a permeability control. Images were
analysed using the InCell Developer v 1.9.2 software (GE Healthcare, Little Chalfont, Bucks, UK) [24].
Not all data fitted a normal Gaussian distribution, therefore, median values were calculated and
compared to elevate the effect of amiodarone.
2.7. Lung Histology
Following lavage, the left and intermediate lung lobes were fixed in 10% neutral buffered formalin.
Three transverse sections were cut through the left lung (superior, median and caudal regions) and
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embedded in paraffin wax blocks. Sections of 3–5 µM were cut and stained with hematoxylin and
eosin for visualization of inflammatory cell infiltrate and assessment of histopathological lesions.
2.8. Mass Spectrometry Imaging and Analysis
The right lung lobe was excised, weighed and laid on a foil lined mega cassette with the lobe gently
spread out. The mega cassette was placed on dry ice to freeze, and then stored in a labelled plastic
bag and transferred to an ultra-cold freezer at −70 to −90 ◦C prior to dispatch. Sample transport was
subsequently carried out on dry ice. Samples were sectioned at 14 µm by cryo-microtome (CM 1850,
Leica, Milton Keynes, UK) and thaw mounted onto glass microscope slides (Superfrost Plus, Thermo
Fisher, Waltham, MA, USA) prior to storage at −80 ◦C until needed. Samples were placed in a vacuum
desiccator for 30 min prior to analysis, returning to room temperature whilst minimizing condensation.
DESI MSI was performed at 50 × 50 or 100 × 100 µm, scan time of 0.48 s and stage speeds of 100
and 200 µm/s respectively. A solvent system of 95:5 methanol:water (v:v) with 0.001 mg/mL raffinose
(lock mass/internal standard) was employed. Quality control and optimization was carried out on
rhodamine (from a red Sharpie pen) or m/z 666 (from a black Staedtler pen) prior to tissue analysis
where an ion intensity of >106 was used as a passing threshold. Additionally, the characteristics of
the eroded spot from the DESI spray were assessed on a thin film of rhodamine sublimated onto
glass [25]: a tightly focussed, approximately circular region clearly eroding through the entire layer in
≤1 s was used.
Data were converted from proprietary Waters.RAW format into imzML using ProteoWizard [26]
and the imzML converter [27], and imported into Matlab (version 2017a and statistics and image
processing toolbox, The Math-Works, Inc., Natick, MA, USA) using SpectralAnalysis [28]. Ion images
were derived from the area under a given peak at full width half maximum.
2.9. Statistics
GraphPad Prism 7.01 software was used for all statistical analyses. Data was analysed for
normality using the Shapiro–Wilk test. BAL cell counts from amiodarone and air-challenged rats
were compared using a two-way ANOVA with a post-hoc Bonferroni test. Morphology and lipid
content data were assessed using a Mann–Whitney test. Statistical significance was evaluated at a 95%
confidence level (p < 0.05).
3. Results
3.1. Assessment of Inflammation and Phospholipidosis Markers in the BAL Cellular Fraction
All dosing protocols included a group of animals (n = 3–5 animals) culled one day following
the final dose. The i.n. study also included a cull on day 7 post-final dose and both aerosol studies
included cull groups on days 7 and 28 post-final dose. All control groups (saline or air treated) showed
outcomes in line with values reported in literature [19,29,30], i.e., total cell counts were normal, and no
inflammatory cells were present in the BAL cellular fraction (Figure 1). Regardless of the administration
route, total BAL cell numbers did not increase in any of the amiodarone-treated groups tested (Figure 1).
Neutrophils were elevated in a single animal in the day 1 cull group of the high-dose aerosol study
(Protocol 2). However, as the animal numbers within this group were low and the effect transient,
the significance of this outcome should not be overly interpreted. A significant (p < 0.001) increase in
eosinophils was also observed in the high-dose aerosol group on cull day 7.
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Figure 1. Effect of intranasal (i.n.), aerosol or oral amiodarone exposure on the total number of cells, 
macrophages, neutrophils and eosinophils recovered by bronchoalveolar lavage (BAL). Rats were 
exposed to amiodarone, sterile saline (SAL) or air (control) at various time points (days) and subjected 
to BAL at day 1, day 7 or day 28 post-dosing (a–c). Total cell number recovered by BAL, (d–f) number 
of alveolar macrophages recovered by BAL, differential counts of (g–i) neutrophils and (j–l) 
eosinophils recovered by BAL. Columns represent mean ± SEM (n = 2–5 per treatment group); two-
way ANOVA with post hoc Bonferroni Test, Difference from respective saline or air controls; * p < 
0.05, *** p < 0.001, statistically significant compared with the respective control, two-way ANOVA 
with post hoc Bonferroni test. 
Figure 1. Effect of intranasal (i.n.), aerosol or oral amiodarone exposure on the total number of cells,
macrophages, neutrophils and eosinophils recovered by bronchoalveolar lavage (BAL). Rats were
exposed to amiodarone, sterile saline (SAL) or air (control) at various time points (days) and subjected
to BAL at day 1, day 7 or day 28 post-dosing (a–c). Total cell number recovered by BAL, (d–f) number
of alveolar macrophages recovered by BAL, differential counts of (g–i) neutrophils and (j–l) eosinophils
recovered by BAL. Columns represent mean ± SEM (n = 2–5 per treatment group); two-way ANOVA
with post hoc Bonferroni Test, Difference from respective saline or air controls; * p < 0.05, *** p <
0.001, statistically significant compared with the respective control, two-way ANOVA with post hoc
Bonferroni test.
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Light microscopy analysis of the BAL macrophage population revealed two distinct morphological
phenotypes of vacuolated macrophages: enlarged macrophages with a finely vacuolated cytoplasm
and macrophages with a coarsely vacuolated cytoplasm (Figure 2a). Previous morphological
characterisation of amiodarone-treated macrophages from our group [4] and others [31,32] have
observed that amiodarone exposure is associated with a characteristic vacuole morphology typified
by one or two very large vacuoles, as shown in Figure 2a, while the enlarged, finely vacuolated
phenotype may be associated with cells in the early stages of apoptosis [33]. In the current study,
amiodarone treatment was associated with increased numbers of finely vacuolated macrophages
for all administration routes, indicating a stress response in the macrophage population to the drug
(Figure 2b–d). These numbers stayed high after dosing was terminated in the aerosol administration
groups. In contrast, only the oral dosing protocol induced high numbers of the characteristic coarsely
vacuolated cells (Figure 2e), typical following systemic amiodarone treatment.
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Figure 2. Morphological evaluation of BAL macrophages using light microscopy. (a) Representative
images (63× ma nification) showing macrophages from control animals (left imag ), enlarged
macrophages with finely vacuolated ytoplasm (centre image) and macrophages with a coarsely
vacuolat d cytoplasm (right image). The prevalen of macrophages with finely vacuolated cytoplasm
(b–d) and coarsely vacuolated cytoplasm (e–g), xpressed as a ercentage of the total macrophage
population at day 1, day 7 and day 28 post-dosing with vehicle control (sali e (SAL) or air) and
amiod rone. Data represents mean ± standard error of the mean (SEM) (n = 2–5 per treatment group); *
p < 0.05, ** p < 0.01, statistically significant compared to respective co trol, two-way ANOVA with post
hoc Bonferroni test, difference from untreated cells.
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The morphological evaluation using light microscopy was corroborated by the HCA assay of the
isolated BAL macrophage population (Figure 3). Only the oral dosing group showed a consistently
elevated percentage of the adherent macrophage population with a larger cellular area, a higher
number of vacuoles, a larger vacuole area and, importantly, elevated phospholipid levels. These
combined results indicate that oral treatment with high dose amiodarone promoted the development
of phospholipidosis in AM without an accompanying lung inflammation, at least for time points
immediately following treatment. The aerosol study, in contrast, failed to induce clear evidence of
phospholipidosis in the BAL cellular fraction (Figure 3 and Figure S1).
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Figure 3. Median cell area (a), number of vacuoles per cell (b), percentage of cell area occupied by
vacuoles (c), intensity of phospholipid stain (d) and neutral lipid stain (e) are reported for macrophages
isolated from BAL on day 1 post-dosing. Each data point represents the mean ± standard error of the
mean (SEM) of triplicate samples per rat (n = 3–6 animals). Data from day 7 of the aerosol studies did
not show any elevation compared to controls and is reported in the supplementary material section
(Figure S1).
3.2. Assessment of Inflammation and Phospholipidosis Markers in Lung Tissue
Lung histology from all groups showed only minor pathologies in a small number of animals, most
of which were considered incidental (Table 1). Minor pathological observations (examples are depicted
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in Figure S2, Supplementary Materials section) were observed in the i.n. and both aerosol groups,
while no significant pathology finding was observed in the oral dosing group. The minimal increases
in alveolar macrophages observed here, especially in the i.n. and low-dose aerosol studies, would not
be considered adverse in view of their low grades and absence of any associated degenerative findings.
The observation of inflammatory cell infiltrates in the high-dose aerosol study could be an indication of
a test-article related effect, since the occurrence is higher in the treatment groups compared to controls.
It is relevant to note that the routine, blinded pathology evaluation of lung tissue slices did not yield
conclusive reports of FAM observations for any treatment group, not even the oral dosing cohorts.
Table 1. Summary of pathology observations in study groups with an observed pathology. Groups with
no pathology observations are not listed. Results depict the number of animals per cohort exhibiting
the pathology.
Cohort Description Pathology
Dosing
Method Treatment Cull Day
Minimal Increases
in Alveolar
Macrophage Numbers
Foci of
Foamy Cells
Minimal Perivascular/Peribronchiolar
Inflammatory Cell Infiltrate (Consisting
of Neutrophils and Eosinophils)
i.n.
Control 1 2/2 0/2 0/2
Amiodarone 1 2/2 0/2 0/2
Control 7 3/3 0/3 0/3
Amiodarone 7 3/3 0/3 0/3
Aerosol:
low dose
Control 1 0/6 0/6 0/6
Amiodarone 1 3/6 1/6 0/6
Control 7 3/6 0/6 0/6
Amiodarone 7 3/6 0/6 0/6
Control 28 2/6 0/6 0/6
Amiodarone 28 3/6 0/6 0/6
Aerosol:
high dose
Control 1 0/6 0/6 0/6
Amiodarone 1 2/6 0/6 3/6
Control 7 1/6 0/6 1/6
Amiodarone 7 1/6 0/6 6/6
As a result of the discrepancies in outcomes between the models characterised here, especially
between the aerosol and oral treatment regimens, it was hypothesised that both the administration
route and dose are likely to have substantial effects on the amount and spatial distribution of drug
reaching the lung. To assess this, MSI analysis was employed to characterise amiodarone distribution
in the lung following oral and high-dose aerosol administration. The spatial distribution of the
amiodarone metabolites, n-desyl-amiodarone, m8 and m11 [34] was evaluated, as well as the presence
and distribution pattern of the phospholipidosis biomarker, di-22:6-bis-monoacylglycerol (BMP; [35]).
However, the detection of BMP is complicated by the potential and even likely presence of di-22:6
phosphatidylglycerol (PG), a structural isotope of BMP.
MSI analysis was able to detect amiodarone (total ion contribution of m/z 646.0214) in lung
slices from animals on day 1 post-dosing in both oral and high-dose aerosol administration studies
(Figure 4a,b). The spatial distribution of aerosolised amiodarone was typical for an inhaled compound
with highly localised concentrations surrounding the airways denoting focal deposition, which
contrasts greatly with the homogenous distribution of amiodarone following oral dosing. The three
amiodarone metabolites, n-desyl-amiodarone, m8 and m11, were also predominantly present on day 1
only, showing a more homogenous distribution across lung tissue. Both amiodarone and its metabolites
were no longer detectable one week post-aerosol dosing (Figure 4d,f,h).
Di-22:6-BMP is a surface-active lipid present in lung surfactant, as well as within lysosome and
endosomes [36]. Elevated cellular concentrations of di-22:6-BMP have been increasingly associated
with drug-induced phospholipidosis [35]. It was therefore of interest to determine whether elevated
signals of di-22:6-BMP (m/z 865.50 with two characteristic fragments: m/z 283 and 327) were present
in amiodarone-treated lung samples in this study. The images in Figure 5 show the distribution of
the di-22:6-BMP parent ion, with a homogenously distributed, low-intensity signal present in all
tissues (Figure 5). Notably, in both the day 1 cull groups from the oral and aerosol dosing studies,
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focal accumulations of di-22:6-BMP are present, often near airways. In the aerosol day 1 study group,
the amiodarone and di-22:6-BMP signals are often co-localised.
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Figure 5. Ion images of m/z 865.51 in lungs of animals following oral (a) and aerosol (b) administration,
showing a higher distribution of the target lipid in a highly localised area of the tissue (possibly
major airways) along with a background in the tissue. Note: the signal could derive from the two
isomeric species di-22:6 BMP and/or di-22:6 PG. Image A represents 44.3 mm by 17.4 mm in the x and y
dimension respectively and image B 46.5 mm by 23.3 mm in the x and y dimension respectively.
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4. Discussion
The accumulation of poorly soluble drugs has been identified as one cause of FAM responses [37],
with some FAM responses being limited to aggregates at the bronchoalveolar junction; however, with
others an associated neutrophilic inflammation is also observed [2]. Furthermore, the FAM distribution
can vary depending on the route of administration. CADs administered systemically have FAMs
distributed throughout the lungs, whereas, when CADs are inhaled FAMs are predominantly localised
at the bronchoalveolar junction and the site of deposition [38].
Our study looked at a single strain of Wistar Han rats with amiodarone administered using four
drug administration protocols. Overall, amiodarone administered at highly varying doses and by
different routes (i.n., aerosol or oral gavage) was well tolerated, with only a mild inflammatory response
observed in the high-dose aerosol study. A comparison of relevant model characteristics published
across the literature highlights the variability observed between dosing protocols, administration
routes and rat strains (Table 2).
Two primary routes of administration are reported in the literature for amiodarone induced
pulmonary toxicity (AIPT) in rats: oral and i.t. Oral dosing of animals leads to marked phospholipidosis
in lung cells and tissue but does not produce a consistent pulmonary inflammatory response (Table 2).
Conversely, i.t. dosing of animals produces an initial inflammatory response observed in BAL samples
and lung tissue [18–20,39] subsequently followed by fibrosis [20,39,40]. A study comparing the
pulmonary responses of hamsters to either oral or i.t. treatment concluded that oral amiodarone
administration led to drug accumulation in lung tissue and significant phospholipidosis without
resulting in fibrosis, whilst i.t. amiodarone treatment produced fibrosis without drug accumulation
and phospholipidosis [12].
The reason for the discrepancy in response to amiodarone may be due to differences in amiodarone
pharmacokinetics following different routes of administration. Amiodarone administered orally
is absorbed slowly and incompletely, [11] and its metabolites have been reported to cause lung
damage [15]. The parent compound, amiodarone, concentrates in organs with high lipid content
(adipose tissues, thyroid and liver) and the lungs [41] with little detected in the blood [7]. Amiodarone
also undergoes first pass metabolism by the enzyme cytochrome P450 in the liver and gastrointestinal
tract, and only small amounts of amiodarone and its metabolites can be found in urine [11]. Amiodarone,
once metabolised to its more polar counterpart n-desyl-amiodarone, accumulates in the lungs to a
greater extent than the parent compound [8,9]. Thus, the more pronounced changes observed with
amiodarone when administered by the oral route may be due to the ability of the lung to sequester
amiodarone and in particular its metabolites [15]. This was supported in our study by MSI analysis of
lung tissue showing evidence of n-desyl-amiodarone, m8 and m11, the two lesser known metabolites of
amiodarone at day 1 post dosing in addition to the presence of the phospholipid marker, di-22:6-BMP.
The HCA assay also indicated increased levels of phospholipid in BAL macrophages, a common
observation following administration of amiodarone [7,8,17,42].
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Table 2. Overview of the characteristics of amiodarone induced phospholipidosis models.
Study Information Reported Outcomes
Route Rat Strain Amiodarone Dosing Protocol Authors Total BAL Counts(×106 cells/mL)
BAL Neutrophils
(×106 cells/mL)
BAL Eosinophils
(×106 Cells/mL)
Macrophage
Phospholipid
Accumulation
Lamellar
Bodies
Foci of Foamy Cells in
Tissue
Oral
HW 1
Rats fed 175, 300, 400 or
500 mg/kg for 6 wk suspended in
0.5% methyl cellulose for 5
days/wk by gavage
Wilson et al., 1991 [7]
High dose group had
significantly more cells
than control or the
175 mg/kg group.
175 mg/kg < 0.5
300 mg/kg < 2
400 mg/kg ~ 2
500 mg/kg ~ 3
Not reported
Yes
(Only in the three
high dose groups)
No
Yes
(Only in the three high
dose groups)
F344 2
Rats treated orally (50, 100,
150 or 200 mg/kg), daily for 1 wk
(5 days/wk)
Reasor et al., 1988 [6] Not reported Not reported Not reported
Yes
(Only in the two high
dose groups)
Yes Yes
LE 3
Rats treated orally 150 mg/kg,
daily for 1 wk (5 days/wk) Reasor et al., 1988 [6] N/A Not reported Not reported No N/A N/A
SD 4
Rats treated orally 150 mg/kg,
daily for 1 wk (5 days/wk) Reasor et al., 1988 [6] N/A N/A N/A No N/A N/A
HW
Rats fed 175 mg/kg suspended in
0.5% methyl cellulose 5 days/wk
by gavage
Wilson and Lippmann,
1990 [15]
No increase in BAL
cell counts No Not reported N/A N/A
Some intra-alveolar
FAM
F344
Rats fed 175 mg/kg suspended in
0.5% methylcellulose 5 days/wk
by gavage
Wilson and Lippmann,
1990 [15]
Total lavage cell count was
increased (p < 0.001)
Increased neutrophils
(p < 0.001) Not reported N/A N/A
AM 5 were much larger
than the HW AM.
Alveolar spaces
contained large FAM 6
F344 Fed 150 mg/kg for 2 weeks bygavage Mazue et al., 1984 [14] N/A N/A N/A
Yes
(Lymph nodes
and lungs)
Yes
Yes, distended FAM
with pale, finely
vacuolated cytoplasm
HW Fed 150 mg/kg for 2 weeks bygavage Mazue et al., 1984 [14] N/A N/A N/A No N/A N/A
SD Fed 150 mg/kg for 2 weeks bygavage Mazue et al., 1984 [14] N/A N/A N/A
Yes
(Lymph nodes only) N/A N/A
HW
100 mg/kg suspended in 1% w/v
methyl cellulose for seven
consecutive days
Patel et al., 2019 1.36 0.00 0.01 Yes(slight increase) N/A No
i.n. HW 6.25 mg/kg, dosed twice at days−2 and 0 Patel et al., 2019 0.70 0.04 0.03 No N/A No
i.t. F344 6.25 mg/kg, dosed twice at days1 and 3 Taylor et al., 2000 [18] ~56 ~14 ~1.4 N/A No Not reported
F344 6.25 mg/kg, dosed twice at days1 and 3 Lee et al., 2013 [19] ~5 ~2 ~0.8
Yes
(Formation of lipid
droplets)
Yes No
Aero.
HW ~3 mg/kg over 30 min on day−2 and 0 Patel et al., 2019 0.91 0.01 0.00 No N/A No
HW 10 mg/kg (day −3) and 30 mg/kg(days −2, 1 and 0) Patel et al., 2019 1.84 0.06 0.03–0.07 No N/A No
1 HW = Han Wistar, 2 F344 = Fischer 344, 3 LE = Long-Evans, 4 SD = Sprague-Dawley; 5 AM = alveolar macrophages, 6 FAM = Foamy Alveolar Macrophages.
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In contrast amiodarone exposure following inhalation does not undergo first pass metabolism [9]
resulting in minimal lung damage due to the lack of production of toxic metabolites. The pulmonary
inflammation observed following inhaled amiodarone may therefore be related to direct toxicity of the
parent compound at higher doses, as observed with our high dose aerosol study, but not in the low
dose aerosol study. However, the doses used in our inhalation study, which were limited by concerns
over animal welfare and avoiding excessive lung inflammation, may have been too low to produce
detectable changes in phospholipid content using the HCA assay, although a more sensitive method
of analysis such as MSI was able to detect di-22:6-BMP in lung tissue slices. The distribution of the
di-22:6-BMP marker following aerosolised administration was highly localised in the airways denoting
focal deposition, which contrasts greatly with the homogenous distribution of amiodarone throughout
lung tissue following oral dosing, and may limit the detection of phospholipids and allow for a more
localised inflammatory response. There was no evidence of amiodarone or its metabolites at day 7
post dosing showing that amiodarone at the dose inhaled was not retained in the lungs and cleared
more rapidly compared to chronic oral amiodarone administration.
In addition to differences observed following administration of amiodarone by different routes,
there are considerable differences in AIPT according to the strain of rat used. A comparative study of
orally treated Sprague-Dawley, Fischer 344 and Wistar Han rats revealed a marked sensitivity of Fischer
344 rats compared to the more moderate response of Sprague-Dawley rats (Table 2). A sub lethal dose
of amiodarone induced lipid storage in the tissues of Fischer, and to a lesser extent Sprague-Dawley,
rats, but not in Wistar rats [14]. This was further confirmed by Reasor et al. who reported that
Sprague-Dawley and Long-Evans hooded rats were less susceptible to amiodarone induced pulmonary
phospholipidosis than Fischer 344 rats [6]. Overall, Wistar Han rats in our study were relatively
insensitive to AIPT under various experimental conditions and this has also been reported in previous
studies [14,15], although, when administered at very high doses (>300 mg/kg) amiodarone has been
shown to induce a mild toxic response [7]. The strain differences observed have been attributed to
the high level of metabolite present in the lungs of Fischer 344 rats that are highly susceptible to the
development of phospholipidosis and/or inflammation [15].
Despite the lack of pulmonary phospholipidosis observed in the Han-Wistar strain following
aerosol administration, this investigation provided the opportunity to evaluate two relatively new
analytical techniques, i.e., HCA and MSI, in the context of conventional inhalation toxicology studies.
MSI, for example, provided vital information on the differences in drug localisation in the lung, thereby
supporting interpretations regarding the relationship between drug distribution and foamy phenotype
development. Further, MSI enabled detection and spatial mapping of the putative phosopholipidosis
biomarker, di-22:6-BMP, on a tissue level, which could potentially be used in toxicological assessments
to complement BAL analysis.
The fluorescence-based HCA methodology is currently used predominantly in an in vitro setting
to screen large numbers of compounds for cytotoxicity, morphological features and lipid profiling [4,24]
prior to animal studies. To examine whether the in vitro culture conditions used in HCA screens reflect
macrophage responses in vivo, it is important to analyse cells harvested from an in vivo exposure
model and directly compare with in vitro data. We previously reported in vitro morphometric data and
neutral lipid/phospholipid content in the rat-derived NR8383 cell line, human-derived, differentiated
U937 cells and rat primary alveolar macrophages harvested from the BAL of naïve Han Wistar rats [24].
The cell lines and primary cells were cultured under submersed conditions and exposed to 10 µM
amiodarone for 24 and 48 h. Direct comparison of the 48 h ex vivo exposure data with the HCA analysis
of BAL macrophages harvested from rats receiving oral amiodarone treatment for seven days (Figure 3)
revealed similar trends in the macrophage responses (Table 3), although all measured parameters
were slightly elevated in cells from the orally dosed animals (Table 3). This elevated response may
result from a longer exposure time and higher exposure concentrations to amiodarone achieved in vivo
compared to the in vitro model. Nonetheless, the data justify the use of the rat cell line, NR8383,
in in vitro screening assays, since the results are comparable to cultured primary cells from the same
Pharmaceutics 2019, 11, 345 15 of 18
species. Further studies will focus on the comparison of human-derived macrophage cell lines and
primary human alveolar cells harvested from lavage, as well as species differences.
Table 3. Comparison of morphometric parameters and neutral lipid/phospholipid content between
the rat cell line, NR8383, primary rat BAL macrophages from naïve rats exposed ex vivo to 10 µM
amiodarone [24] and primary rat BAL macrophages harvested from Han Wistar rats treated orally with
amiodarone (Figure 3).
Parameter Rat NR8383Cell Line [24]
Rat Primary BAL
Macrophages: Ex Vivo
48 h Exposure [24]
Rat Primary BAL Macrophages:
Oral Dosing Study
Cell area (span of values) (µm2) 113–201 165–265 170–250
Median number of vacuoles per cell 5 10 14
Median vacuole area per cell area (%) 10 12 27
LipidTOXTM red fluorescence intensity
fold-change: amiodarone vs. untreated/naive
2.7 2.8 6.0
LipidTOXTM green fluorescence intensity
fold-change: amiodarone vs. untreated/naive
1.3 1.2 1.6
5. Conclusions
The current study was used to investigate two main research questions: first, does aerosol
administration of amiodarone provide a better model of pulmonary FAM for safety investigations of
inhaled medicines? Secondly, do FAM harvested from the BAL of amiodarone-treated rats show similar
characteristics to cultured macrophage cells treated in vitro with amiodarone? Our present findings
indicate that inhaled amiodarone induces transient pulmonary inflammation with little damage to the
lungs of Wistar rats, and induces some finely vacuolated AM with no change in macrophage numbers.
However, the prevalence of FAM was not as prominent as has been reported following systemic
administration of this drug. These observations suggest that the FAM-inducing effect of amiodarone is
best achieved by systemic administration and that inhaled amiodarone cannot be used as a positive
control for inducing FAM in studies investigating the safety of inhaled medicines in vivo. Nonetheless,
the study did reveal that macrophages harvested from the BAL of rats dosed orally with amiodarone
over seven days showed similar trends in a fluorescence-based HCA assay, indicating that in vitro
testing of novel compounds for FAM-inducing effects may be predictive of FAM development in vivo.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/7/345/s1,
Figure S1: Median cell area (a), number of vacuoles per cell (b), percentage of cell area occupied by vacuoles
(c), intensity of phospholipid stain (d) and neutral lipid stain (e) are reported for macrophages isolated from
BAL on day 7 post-dosing. Each data point represents the mean ± standard error of the mean (SEM) of triplicate
samples per rat (n = 3–6 animals), Figure S2: Histopathology (×10 magnification) of lung tissue exposed to
amiodarone. Representative images of lung tissue harvested at day 1 and day 7 following treatment (amiodarone)
or air/saline control.
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